04th week of 2010 patent applcation highlights part 46 |
Patent application number | Title | Published |
20100022433 | Alpha-Amylase Mutants with Altered Properties - The present invention relates to variants (mutants) of parent Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits altered stability, in particular at high temperatures and/or at low pH relative, and/or low Ca | 2010-01-28 |
20100022434 | LIQUID DETERGENT COMPOSITION EXHIBITING ENHANCED ALPHA-AMYLASE ENZYME STABILITY - Embodiments of the present aqueous liquid or gel detergent composition comprise boric acid or a boron compound capable of forming boric acid in the composition, a polyhydroxy compound, calcium ions, water, and an α-amylase enzyme at least 80% homologous with the α-amylase enzyme of SEQ ID NO: 2. | 2010-01-28 |
20100022435 | METHOD OF PRODUCING ADDITION PRODUCTS OF COMPOUNDS CONTAINING SiH GROUPS ONTO REACTANTS HAVING ONE DOUBLE BOND IN AQUEOUS MEDIA - The invention relates to a method of producing organically modified siloxanes and silanes by noble-metal-catalyzed reaction of siloxanes and/or silanes having at least one SiH group with a compound having one double bond, wherein the reaction is carried out in the presence of water. | 2010-01-28 |
20100022436 | Detergents Containing Polycarboxylic Acid Polymers - The present invention relates to methods and polymers based upon vinyl type monomers that contain pendant carboxylic acid groups and ester group functionality. The polymers may be prepared under selected conditions of partial neutralization to provide relatively high conversions and/or relatively high values of molecular weight and/or selected amounts of repeating unit tacticity. The polymers may then be used in detergent formulations. | 2010-01-28 |
20100022437 | Liquid Support - Agglomerating carrier materials in the presence of a granulation liquid with a carbohydrate content and subsequent incorporation of a liquid, such as a perfume oil, yields fluid-containing particles that, even at an elevated liquid loading, exhibit very good powder properties and reliably retain the incorporated liquid even in aggressive solid matrices. These fluid-containing particles may be used, for example, for fragrancing purposes. | 2010-01-28 |
20100022438 | Method of separating carbon nanotubes - A method of separating carbon nanotubes having substantially the same diameter including the steps of: providing a sample of carbon nanotubes; separating individual nanotubes within the sample, and mixing with a solution comprising fibrous protein fibrils so that at least some individual nanotubes form a complex with the protein fibrils, and separating out those nanotubules which have formed a complex. Preferably the protein is collagen. The separated nanotubes can be used in the fields of electronics, medical and materials science. | 2010-01-28 |
20100022439 | Nanostructures with High Load of Active Agents - The present invention provides an improved method of loading silica nanostructures with an active agent, comprising exposing a mixture comprising a liquid medium containing an active agent and silica nanostructures to reduced air pressure for a time period, and then returning the mixture to atmospheric air pressure at the end of the time period. | 2010-01-28 |
20100022440 | VH4 Codon Signature For Multiple Sclerosis - The present invention provides for the diagnosis and prediction of multiple sclerosis (MS) in subject utilizing a unique a codon signature in VH4 expressing B cells that has now been associated with MS and not with any other autoimmune disease. | 2010-01-28 |
20100022441 | N-TERMINAL POLYSIALYLATION - The present invention relates to a composition comprising a population of polysaccharide derivatives of a protein, wherein the protein is insulin or an insulin-like protein and the polysaccharide is anionic and comprises between 2 and 125 saccharide units, and wherein the population consists of substantially only N-terminal derivatives of the protein. Typically, the polysaccharide is PSA. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds. | 2010-01-28 |
20100022442 | COMPOSITIONS AND METHODS FOR INCREASING SERUM ANTIOXIDANT CONCENTRATIONS, DECREASING SERUM TRIGLYCERIDE LEVELS, INHIBITING INSULIN-RECEPTOR SIGNALING ACTIVITY, INCREASING SERUM GHRELIN LEVELS, AND DECREASING SERUM TNF-ALPHA LEVELS - Compositions and methods are provided for increasing serum antioxidant levels, decreasing serum levels of oxidative chemical species, inhibiting insulin-receptor signaling activity, decreasing triglycerides levels, increasing serum ghrelin levels, and decreasing serum TNF-alpha levels. Compositions provided comprise a mixture of zinc-charged, fragmented proteins derived, for example, from serum or milk. Compositions are administered in a therapeutically effective amount to, for example, reduce oxidative stress levels in a mammalian subject. | 2010-01-28 |
20100022443 | DERIVATISATION OF ERYTHROPOIETIN (EPO) - The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds. | 2010-01-28 |
20100022444 | COMBINATION THERAPY FOR MODULATION OF ACTIVITY AND DEVELOPMENT OF CELLS AND TISSUES - The invention as disclosed herein provides methods and compositions for modulation of development and activities of cells and tissues in a subject in need of treatment thereof. The inventive methods and compositions involve the use of a combination therapy that comprises at least two active compositions, the first active composition comprising a balanced PC and an essential fatty acid composition and the second active composition comprising a growth factor, in a suitable carrier or diluent, wherein the combination therapy modulates development and activities of cells and tissues in the subject. | 2010-01-28 |
20100022445 | BIOLOGICALLY ACTIVE PEPTIDES - A peptide or peptide derivative comprising:
| 2010-01-28 |
20100022446 | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 2010-01-28 |
20100022447 | COMPOSITION FOR TREATING CANCER AND USE THEREOF - The present invention provides a cyclic peptide containing RRXR motif. The present invention also provides a composition comprising the said cyclic peptide and a pharmaceutical acceptable carrier. The present invention further provides a method for treating cancer. | 2010-01-28 |
20100022448 | PEPTIDES - An internally-constrained cyclic oligopeptide comprising a ring of at least six amino acids for specifically binding to a target ligand, wherein the ring comprises a plurality of amino acid domains, each domain comprising at least two epitope-forming amino acids, and two or more associating functional groups positioned so that they form one or more intra-cyclic associations; whereby the cyclic oligopeptide is constrained in a single conformation so that the epitope-forming amino acids form an epitope in each domain, each epitope being capable of specifically binding to a target ligand. | 2010-01-28 |
20100022449 | RECEPTOR-AVID EXOGENOUS OPTICAL CONTRAST AND THERAPEUTIC AGENTS - Cyanine and indocyanine dye compounds and bioconjugates are disclosed. The present invention includes several cyanine and indocyanine dyes, including bioconjugates of the same, with a variety of bis- and tetrakis (carboxylic acid) homologues. The compounds of the invention may be conjugated to bioactive peptides, carbohydrates, hormones, drugs, or other bioactive agents. The small size of compounds of the invention allows favorable delivery to tumor cells as compared to larger molecular weight imaging agents. Further, use of a biocompatible organic solvent such as dimethylsulfoxide may be said to assist in maintaining the fluorescence of compounds of the invention. The compounds and bioconjugates herein disclosed are useful in a variety of medical applications including, but not limited to, diagnostic imaging and therapy, endoscopic applications for the detection of tumors and other abnormalities, localized therapy, photoacoustic tumor imaging, detection and therapy, and sonofluorescence tumor imaging, detection and therapy. | 2010-01-28 |
20100022450 | OCTREOTIDE IMPLANT HAVING A RELEASE AGENT - Methods, formulations and kits are described that allow for the controlled release of octreotide, e.g., octreotide acetate, in a subject. | 2010-01-28 |
20100022451 | USE OF INFANT FORMULA WITH REDUCED PROTEIN CONTENT - A method of continuously reducing the circulating level of insulin like growth factor 1 (IGF-1) in the first few months of the life of an infant comprises administering to the 5 infant a nutritional composition comprising proteins in an amount such that the composition contains less than 2.25 g of protein per 100 kcal. As IGF-1 is known to be a key control point in nutritional regulation of growth, this may offer a method of reducing the risk of developing obesity in later life. | 2010-01-28 |
20100022452 | Nanobodies for the treatment of aggregation-mediated disorders - The present invention relates to improved Nanobodies™ against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes. | 2010-01-28 |
20100022453 | NoGo Receptor 1 and Fibroblast Growth Factor Interactions - Compositions and methods useful in promoting neuronal growth, synaptic transmission, or neuronal regeneration are described, including, for example, a polypeptide comprising a fragment of NgR1, wherein the NgR1 fragment has reduced FGF2 binding as compared to wild-type NgR1. Also described are chimeric polypeptides comprising the NgR1 fragment and compositions comprising the fragment or chimeric polypeptide. Nucleic acids, vectors and expression systems are also described which encode the fragments and polypeptides. These compositions can be used in combination with FGF2 to promote neurite outgrowth or neuronal regeneration and can be used to treat central nervous systems diseases and disorders. | 2010-01-28 |
20100022454 | Peptides with High Affinity for the Prolactin Receptor - The present invention is concerned with peptides binding to the prolactin receptor, wherein said peptides have an improved binding via binding site 1 (BS1) to the prolactin receptor. In one embodiment, said improved binding is achieved by mutation of positions 61, 71 and 73. | 2010-01-28 |
20100022455 | THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability. | 2010-01-28 |
20100022456 | Dimeric Prolactin Receptor Ligands - The patent application relates to antagonistic dimers of prolactin molecules and their use in treating cancer. | 2010-01-28 |
20100022457 | Sustained release glp-1 receptor modulators - The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation. | 2010-01-28 |
20100022458 | METHODS FOR TREATING ACUTE ACOUSTIC TRAUMA - The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition includes compounds which function as free radical traps such as phenyl butyl nitrone (PBN), free radical scavengers, such as edaravone, resveratrol, ebselen and iron chelator and compounds from the family of antioxidant compounds including, but not limited to, N-acetylcysteine (NAC), Acetyl-L-Carnitine (ALCAR), glutathione monoethylester, ebselen, D-methionine and carbamathione. The compositions of the current invention may be delivered by injections or orally. | 2010-01-28 |
20100022459 | Peptides directed for diagnosis and treatment of amyloid-associated diseases - Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X—Y or Y—X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases. | 2010-01-28 |
20100022460 | C-PHENYL GLYCITOL COMPOUND - Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action. A C-phenyl glycitol compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof or a hydrate thereof | 2010-01-28 |
20100022461 | Novel Derivatives of Cyclic Compound And The Use Thereof - Disclosed is tonovel cyclic derivatives having potent inhibiting effect on melanin formation and skin hyper-pigmentation activity with no adverse response to skin. They can be used as the therapeutics for treating and preventing the skin disease caused by over-reproduced melanin. | 2010-01-28 |
20100022462 | APPETITE SUPPRESSANT AND COLON CLEANSING COMPOSITION - The present invention provides low calorie, high potency, sugar free compositions and methods for making and using the same. In one embodiment, the composition of the present invention can be used to reduce daily food intake and facilitate detoxification and weight loss. | 2010-01-28 |
20100022463 | FEED ADDITIVE FOR LAYING HEN AND FEED CONTAINING THE SAME - A feed additive for laying hens comprising lactobionic acid or a lactobionic acid salt and a feed characterized by containing a feed additive for laying hens comprising lactobionic acid or a lactobionic acid salt and a feed. Namely, a feed additive for laying hens, which is excellent in effect of reinforcing eggshells, shows a particularly remarkable effect of improving eggshell qualities in the second half of the laying period, relieves stress caused by forced molting, cage transfer and so on and can inhibit lowering in the egg-laying rate. | 2010-01-28 |
20100022464 | FUNCTIONAL FOOD COMPOSITION THAT IS RICH IN PHENOLIC COMPOUNDS AND USE OF SAID COMPOSITION - The invention relates to a functional food composition rich in phenolic compounds, obtained from the combination of citric and olive species extracts, comprising: between 5 and 25% of oleuropein; between 0.1 and 1% of verbascoside, between 0.1 and 1% of hydroxytyrosol, between 1 and 5% of neohesperidin; between 1 and 10% by weight of naringin; between 0.5 and 5% of naringenin and between 0.1 and 2% of apigenin, and its use in food products and supplements. | 2010-01-28 |
20100022465 | METHOD OF TREATING BLEPHARITIS - The present invention relates to a method for treating non-infectious, inflammatory chronic posterior blepharitis in a subject. The present invention also relates to a method for treating chronic posterior blepharitis in a subject for over two weeks. The method comprises identifying a subject in need thereof, and topically administering to the eye of the subject a pharmaceutical formulation consisting essentially of an effective amount azithromycin. The present invention further relates to a method for treating dry eye secondary to blepharitis in a subject. The method comprises the steps of: identifying a subject suffering from dry eye secondary to posterior blepharitis, and topically administering to the eye of the subject a pharmaceutical formulation comprising an effective amount of azithromycin. The present invention further relates to method for reducing contact lens intolerance of a subject due to blepharitis or dry eye secondary to blepharitis. | 2010-01-28 |
20100022466 | THERMALLY-TARGETED DELIVERY OF MEDICAMENTS INCLUDING DOXORUBICIN - Elastin-like polypeptide (ELP) serves as a vector for thermally-targeted delivery of therapeutics, including cytotoxic chemotherapeutic drugs such as doxorubicin. Examples of an ELP-based delivery vehicle can comprise: (1) a cell penetrating peptide, such as a Tat protein, (2) ELP, and (3) the lysosomally degradable glycylphenylalanylleucylglycine (GFLG) spacer and a cysteine residue conjugated to therapeutic such as doxorubicin, or a analog thereof. | 2010-01-28 |
20100022467 | ANTI-CANCER PHOSPHONATE ANALOGS - The invention is related to phosphorus substituted anti-cancer compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2010-01-28 |
20100022468 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION - The present invention provides nucleoside cyclic phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as pre-cursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside cyclic phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside cyclic phosphoramidates of the present invention. | 2010-01-28 |
20100022469 | ANTHELMINTHIC FORMULATIONS - The present invention relates to veterinary or pharmaceutical antiparasitic formulations which may comprise a macrocyclic lactone, one or more alcohol cosolvents and an oil wherein the crystallization of the macrocyclic lactone is minimalized. This invention also provides for, inter alia, antiparasitic formulations for the treating, controlling and preventing of endo- and ectoparasite infections in warm-blooded animals, such as livestock. | 2010-01-28 |
20100022470 | METHOD FOR TREATING ALLERGIC DISEASES - The present invention relates to use of polysaccharides obtained from | 2010-01-28 |
20100022471 | Oral Moisturizer for Alleviating Dry Mouth - An oral moisturizer is disclosed to provide relief from dry mouth. The moisturizer may be provided in different flavors that are palatable, with clinical benefits such as anti-nausea, appetite stimulant, etc., in addition to relief from the deteriorating dental effects of dry mouth. One disclosed oral moisturizer includes glycerin, xylitol, sodium hyaluronate, cetylpyridinium chloride, polysorbate surfactants and a palatable flavor. | 2010-01-28 |
20100022472 | LIQUID, EYE-INSTILLABLE PREPARATIONS COMPRISING SODIUM HYALURONATE - A liquid, eye-instillable preparation comprises a viscosity-enhancing agent comprised of one or both of sodium hyaluronate and chondroitin sulphate, a preservative comprised of polyhexanide, and one or more carriers in which the agent and the preservative are dispersed. | 2010-01-28 |
20100022473 | USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES ASSOCIATED WITH VASCULATURE - This invention provides for the use of compounds represented by the structure of the general formula (A): | 2010-01-28 |
20100022474 | Polymer Controlled Induced Viscosity Fiber System and Uses Thereof - The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to a method of incorporating soluble fiber into a liquid product without the typical negative organoleptic or physical stability issues. The invention also relates to a method of inducing the feeling of fullness and satiety by feeding the induced viscosity fiber system. | 2010-01-28 |
20100022475 | NOVEL TRIAZOLOPYRIMIDINE DERIVATIVES - The present invention relates to novel triazolopyrimidine derivatives of formula I as active ingredients which have microbiocidal activity, in particular fungicidal activity(I): wherein the substituents are as defined in claim | 2010-01-28 |
20100022476 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER - The invention provided a compound of formula: (I) for use in the treatment of disease, in particular proliferative diseases such as cancer and for use in the preparation of medicaments for use in the treatment of proliferative diseases; the invention also processes for the preparation of such compounds, as well as pharmaceutical compositions containing them as active ingredient. | 2010-01-28 |
20100022477 | FUSED AROMATIC PTP-1B INHIBITORS - The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes. | 2010-01-28 |
20100022478 | CHIRAL COMPOUNDS SUBSTITUTED WITH PHOSPHONATE ACID ESTER FUNCTIONS OR PHOSPHONIC ACID FUNCTIONS - The present invention relates to novel compounds that contain PNA units substituted with phosphonic acid ester functions or phosphonic acid functions, and have at least one chiral center. The compounds may be used for the treatment of viral diseases, such as AIDS. | 2010-01-28 |
20100022479 | CELLULAR GRADIENT POLYMER COMPOSITES - The invention relates to a foamed polymer composite product incorporating several fillers and/or fibres and several pores characterized by the fact that it shows two distinct gradients, namely a filler and/or fibre density gradient and a pore density gradient. The polymer composite according to the invention may advantageously be used in tissue engineering, bone replacement, consumer goods, transportation or in any other suitable field. The invention also includes a process for manufacturing said polymer composite. | 2010-01-28 |
20100022480 | Solid Oral Dosage Form Containing An Enhancer - The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form. | 2010-01-28 |
20100022481 | Drug Carriers, Their Synthesis, and Methods of Use Thereof - Drug carriers, methods of synthesizing, and methods of use thereof are provided. | 2010-01-28 |
20100022482 | aSMase inhibitors - The present invention relates to compounds of formula | 2010-01-28 |
20100022483 | Substituted Tetracycline Compounds - The present invention pertains, at least in part, to methods of treating a microorganism-associated infection in a subject comprising administering to said subject an effective amount of a tetracycline compound. | 2010-01-28 |
20100022484 | 4-Chromenonyl-1,4-dihydropyridines and their use - The present application relates to novel 4-chromenonyl-1,4-dihydropyridines, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders. | 2010-01-28 |
20100022485 | FORMULATIONS COMPRISING A VITAMIN AND THE USE THEREOF TO MAKE FORTIFIED FEED AND PERSONAL CARE FORMULATIONS - The invention relates to aqueous formulations comprising alkoxylated castor oils with 15-25 ethyleneoxy units and a vitamin, preferably a fat-soluble vitamin, as well as to the use of such formulations in the process to administer the vitamin to an animal, or to make personal care formulations comprising the vitamin. | 2010-01-28 |
20100022486 | COMPOUNDS - The present invention relates to substituted 3-Aminopyrazole compounds of formula (I): | 2010-01-28 |
20100022487 | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject - A method, device, or kit is provided which maintain a substantially physiological cyclic pre-menopausal level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on pre-menopausal cyclic steroid hormone levels of the subject and on current cyclic steroid hormone levels of the subject, wherein the at least one treatment regimen is configured to maintain the subject's one or more steroid hormones or metabolites or modulators thereof at substantially physiological cyclic pre-menopausal levels. The method, device, or kit can be used for the treatment of a disease or condition in the mammalian subject. | 2010-01-28 |
20100022488 | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject - A method, device, or kit is provided which maintain a substantially physiological cyclic pre-menopausal level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on pre-menopausal cyclic steroid hormone levels of the subject and on current cyclic steroid hormone levels of the subject, wherein the at least one treatment regimen is configured to maintain the subject's one or more steroid hormones or metabolites or modulators thereof at substantially physiological cyclic pre-menopausal levels. The method, device, or kit can be used for the treatment of a disease or condition in the mammalian subject. | 2010-01-28 |
20100022489 | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject - A method, device, or kit is provided which maintain a substantially physiological level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on steroid hormone levels prior to disease diagnosis in the subject and on current steroid hormone levels in the subject, wherein the at least one treatment regimen is configured to maintain the subject's one or more steroid hormones or metabolites or modulators thereof at substantially physiological pre-disease levels. The method, device, or kit can be used for the treatment of a disease or condition in the mammalian subject. | 2010-01-28 |
20100022490 | Zilpaterol Enantiomer Compositions and Methods of Making and Using Such Compositions - This invention is directed generally to zilpaterol enantiomer compositions and, in particular, to compositions comprising the 6R,7R zilpaterol enantiomer. This invention is also directed to processes for making such compositions; methods for using such compositions to, for example, increase the rate of weight gain, improve feed efficiency, and/or increase carcass leanness in livestock, poultry, and/or fish; and uses of such compositions to make medicaments. This invention is further directed to methods for determining the absolute configurations of zilpaterol enantiomers. | 2010-01-28 |
20100022491 | 4-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-7YL COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR ACTIVITY - The present invention provides compounds of formula (I) (A chemical formula should be inserted here—please see paper copy enclosed herewith) wherein Ra, Rb, R | 2010-01-28 |
20100022492 | THERAPEUTIC CAUSING CONTRACTION OF MUCOSAL TISSUE, METHOD OF TREATING DISEASES RELATING TO MUCOSAL TISSUES, INJECTOR AND THERAPEUTIC SET - The invention provides for a therapeutic causing contraction of a mucosal tissue whereby various diseases relating to mucosal tissues can be easily, safely and treated with minimal invasiveness, a method of treating various diseases relating to mucosal tissues with the use of the therapeutic causing contraction of a mucosal tissue, and an injector and a therapeutic set usable in the treatment method. The invention also encompasses a therapeutic causing contraction of nasal mucosal tissue containing ethanol as the active ingredient preferably together with a steroid and/or an antihistaminic agent; a method of treating diseases with mucosal inflammation using the above therapeutic causing contraction of a mucosal tissue, and an injector and a therapeutic set usable in the treatment method. | 2010-01-28 |
20100022493 | USE OF MOMETASONE FUROATE FOR TREATING AIRWAY PASSAGE AND LUNG DISEASE - The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed. | 2010-01-28 |
20100022494 | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject - A method, device, or kit is provided which maintain a substantially physiological level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on steroid hormone levels prior to disease diagnosis in the subject and on current steroid hormone levels in the subject, wherein the at least one treatment regimen is configured to maintain the subject's one or more steroid hormones or metabolites or modulators thereof at substantially physiological pre-disease levels. The method, device, or kit can be used for the treatment of a disease or condition in the mammalian subject. | 2010-01-28 |
20100022495 | MODULATING ENDOPLASMIC RETICULUM STRESS IN THE TREATMENT OF TUBEROUS SCLEROSIS - Endoplasmic reticulum stress has been found to be associated with the genetic disease tuberous sclerosis. Tuberous sclerosis is cause by defects in the two genes, TSC1 and TSC2. Agents that modulate ER stress may be used to treat tuberous sclerosis and other hamartomatous diseases. In particular, 4-phenyl butyric acid (PBA) has been shown to reduce ER stress is TSC-deficient cells. Other compounds useful in reducing ER stress are chemical chaperones such as trimethylamine N-oxide arid glycerol may also be useful in treating tuberous sclerosis. The present invention provides methods of treating a subject suffering from tuberous sclerosis using ER stress reducers such as PBA, TUDCA, UDCA, and TMAO. Methods of screening for ER stress reducers by identifying agents that reduce levels of ER stress markers in TSC-deficient cells are also provided. These agents may find use in methods and pharmaceutical compositions for treating tuberous sclerosis. | 2010-01-28 |
20100022496 | GALENICAL FORM FOR THE ADMINISTRATION OF ACTIVE INGREDIENTS BY TRANSMUCOUS MEANS - A galenical form for the administration transmucously of at least one active ingredient, characterized in that the active ingredient is in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 20% by mass of alcohol so as to allow rapid absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. Uses of the galenical form are also disclosed. | 2010-01-28 |
20100022497 | Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject - A method for treating cardiovascular disease in a mammalian subject includes providing to the subject at least one treatment regimen including at least one estrogen receptor modulator, wherein the at least one treatment regimen is determined based on the APOE allelic profile in the subject, and based on the steroid hormone levels prior to disease diagnosis and on current steroid hormone levels in the subject. | 2010-01-28 |
20100022498 | STEROIDS AS AGONISTS FOR FXR - The invention relates to compounds of formula (I): | 2010-01-28 |
20100022499 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS - Heterocyclic compounds having a relatively flexible backbone are used to create combinatorial libraries that permit screening for lead compounds and selection of drug candidates for a variety of uses in human and veterinary medicine as well as in agriculture. The compounds of the library generally differ in ring size and chirality of substituents on the ring. Also disclosed are methods for providing and screening these libraries, preferably in an automated or computerizable manner, such as by using a computer program to virtually screen the compounds in order to identify those that are predicted to have bioactive conformations that should give rise to desirable biological effects. | 2010-01-28 |
20100022500 | Macrocyclic Lactams and Pharmaceutical Use Thereof - The present invention relates to novel macrocyclic compounds of the formula | 2010-01-28 |
20100022501 | INJECTABLE OR ORALLY DELIVERABLE FORMULATIONS OF AZETIDINE DERIVATIVES - The invention concerns injectable or orally deliverable binary or ternary formulations of azetidine derivatives. The azetidine derivatives used in the inventive pharmaceutical compositions can be represented by the general formulae (Ia) or (Ib), wherein Ar is an aromatic or heteroaromatic group optionally substituted by one or more among (C | 2010-01-28 |
20100022502 | AMINOPYRIDINES AND AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2010-01-28 |
20100022503 | AMINOPYRAZOLE KINASE INHIBITORS - The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents. | 2010-01-28 |
20100022504 | METHODS FOR TREATING LATENT TUBERCULOSIS - A method for treating individuals affected with latent tuberculosis comprising a step of administering an effective amount of one or more carbapenem compounds to the said individuals. | 2010-01-28 |
20100022505 | BICYCLIC HETEROCYCLES, DRUGS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR PRODUCTION THEREOF - The present invention relates to bicyclic heterocycles of general formula | 2010-01-28 |
20100022506 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 2010-01-28 |
20100022507 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2010-01-28 |
20100022508 | ANTIVIRAL COMPOUNDS - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2010-01-28 |
20100022509 | Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same - The present invention utilizes three families of bacterial enzymes, which play a key role in mycothiol biosynthesis. The three families are bacterial cysteine:glucosaminyl inositol ligases (MshC) with catalytic ligase activity for ligation of glucosaminyl inositol and cysteine, bacterial acetyl-CoA:Cys-GlcN-Ins acetyltransferases (MshD) with catalytic activity for addition of an acetyl group to Cys-GlcN-Ins and bacterial MshA glycosyltransferase with catalytic activity for production of GlcNAc-Ins. The invention provides methods for using the mycothiol biosynthesis ligases, acetyltransferases or glycosyltransferases in drug screening assays to determine compounds that inhibit activity. The invention also provides inhibitors of the production or activity of the enzymes of mycothiol biosynthesis, and use of the inhibitors for treating microbial infection. | 2010-01-28 |
20100022510 | Crystalline Forms - The present invention is directed to a crystalline form the pharmaceutical compound 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine as well as compositions, preparations, and pharmaceutical uses thereof. | 2010-01-28 |
20100022511 | Stabilized Atypical Antipsychotic Formulation - A pharmaceutical composition that contains an atypical antipsychotic drug and succinic acid, fumaric acid or a mixture of succinic acid and fumaric acid. | 2010-01-28 |
20100022512 | COMPOSITIONS OF CHK1 INHIBITORS AND CYCLODEXTRIN - Compositions containing at least one Chk1 inhibitor and at lease one cyclodextrin are disclosed. Also disclosed are methods of treating a cancer or potentiating a cancer treatment with a composition comprising at least one Chk1 inhibitor and at least one cyclodextrin. | 2010-01-28 |
20100022513 | ORGANIC COMPOUNDS - The invention relates to compounds of formula (I): | 2010-01-28 |
20100022514 | Heterocycle Compounds and Methods of Use Thereof - The invention relates to the use of compounds in the treatment of deacetylase-associated diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases. | 2010-01-28 |
20100022515 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising compound of following formula (I), and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119 (G protein-coupled receptor 119) such as obesity, diabetes and hyperlipidemia. | 2010-01-28 |
20100022516 | 4,5-Disubstituted-2-aryl pyrimidines - 4,5-disubstituted-2-arypyrimidines of Formula I and Formula II are provided: | 2010-01-28 |
20100022517 | OPHTHALMIC FORMULATION OF RHO KINASE INHIBITOR COMPOUND - The present invention relates to an aqueous pharmaceutical formulation comprising at least one inhibitor of Rho-associated protein kinase (ROCK). The aqueous pharmaceutical formulation comprises 0.01-0.4% w/v of ROCK inhibitor(s), a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 220-360 mOsm/kG, at a pH between 6.3 to 7.8, wherein the ROCK inhibitor, the surfactant, and the tonicity agent are compatible in the formulation. The aqueous ophthalmic formulations of this invention have an increased ocular bioavailability and/or aqueous humor concentrations without a concomitant increase in systemic concentrations. The present invention further provides a method of reducing intraocular pressure, particularly a method of treating glaucoma, by administering the aqueous pharmaceutical formulation to a subject. | 2010-01-28 |
20100022518 | NOVEL HETEROCYCLYL COMPOUNDS - The invention is concerned with novel heterocyclyl compounds of formula (I): | 2010-01-28 |
20100022519 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF - The invention relates to Heterocyclic-Substituted Piperidine Compounds, compositions comprising an effective amount of a Heterocyclic-Substituted Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Heterocyclic-Substituted Piperidine Compound. | 2010-01-28 |
20100022520 | MALONYL-COA ACETYLTRANSFERASE INHIBITORS AGAINST ANTIBIOTIC RESISTANT BACTERTIA - Compounds characterized by thiolactone or thiomorpholino cores display useful antibiotic and radioprotective properties. The latter properties are believed to arise from an ability of the compounds to inhibit proteins involved in apoptosis. | 2010-01-28 |
20100022521 | COMPOUNDS - The present invention relates to new mGluR1 and mGluR5 receptor subtype preferring ligands of formula (I) wherein X represents a group selected from SO, SO2; Y represents a group selected from (CH | 2010-01-28 |
20100022522 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS - The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. | 2010-01-28 |
20100022523 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS - The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R | 2010-01-28 |
20100022524 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS - The invention includes tetrahydroquinoline and related compounds of formula I, and pharmaceutical compositions thereof, that exhibit useful antibacterial activity against a wide range of human and veterinary pathogens. | 2010-01-28 |
20100022525 | Arginine Derivatives with NP-I Antagonistic Activity - The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists. | 2010-01-28 |
20100022526 | PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES - The present invention relates to compounds of formula (I) wherein R | 2010-01-28 |
20100022527 | BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISEASES - The present invention relates to novel substituted spirotetronic acids (I) in which R | 2010-01-28 |
20100022528 | TETRA-SUBSTITUTED NDGA DERIVATIVES VIA ETHER BONDS AND CARBAMATE BONDS AND THEIR SYNTHESIS AND PHARMACEUTICAL USE - Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers. | 2010-01-28 |
20100022529 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET - The present invention provides amidophenoxyindazole compounds useful in the treatment of cancer. | 2010-01-28 |
20100022530 | TETRAHYDROBENZOISOXAZOLE AND TETRAHYDROINDAZOLE DERIVATIVES AS MODULATORS OF THE MITOTIC MOTOR PROTEIN - Compounds of the formula (I) in which A | 2010-01-28 |
20100022531 | NOVEL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF - Compounds are disclosed that have a formula represented by the following (1), the compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others. | 2010-01-28 |
20100022532 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS - The invention provides low molecular weight compounds, namely 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase. | 2010-01-28 |